Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Jim Birchenough has maintained an Equal-Weight rating on Regulus Therapeutics (NASDAQ:RGLS) and increased the price target from $2 to $3.
March 13, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Regulus Therapeutics and raised the price target from $2 to $3.
The increase in price target by a reputable analyst like Jim Birchenough suggests a positive outlook on the stock's future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90